Your browser doesn't support javascript.
loading
Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
García-Corbacho, Javier; Indacochea, Alberto; González Navarro, Azucena E; Victoria, Iván; Moreno, Débora; Pesántez, David; Angelats, Laura; Modrego-Sanchez, Andrea; Sanfeliu, Esther; Castillo, Oleguer; Blasco, Paula; Mezquita, Laura; Viñolas, Nuria; Nogué, Miquel; Galván, Patricia; Adamo, Barbara; Basté, Neus; Sauri, Tamara; Juan, Manel; Prat, Aleix; Schettini, Francesco.
Afiliação
  • García-Corbacho J; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Indacochea A; Medical Oncology Department (UGCI), Virgen de La Victoria and Regional University Hospital / IBIMA, Málaga, Spain.
  • González Navarro AE; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Victoria I; Medical Oncology Department, Hospital General of Granollers, Barcelona, Spain.
  • Moreno D; Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Pesántez D; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Angelats L; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Modrego-Sanchez A; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Sanfeliu E; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Castillo O; Translational Genomics and Targeted Therapies in Solid Tumours Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Blasco P; Medical Oncology Department, University Hospital, 12 de Octubre, Madrid, Spain.
  • Mezquita L; Translational Genomics and Targeted Therapies in Solid Tumours Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Viñolas N; Pathology Department, Diagnostic Biomedical Center, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Nogué M; Translational Genomics and Targeted Therapies in Solid Tumours Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Galván P; Translational Genomics and Targeted Therapies in Solid Tumours Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Adamo B; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Basté N; Translational Genomics and Targeted Therapies in Solid Tumours Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Sauri T; Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, c. Casanova, 143, 08036, Barcelona, Spain.
  • Juan M; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Prat A; Translational Genomics and Targeted Therapies in Solid Tumours Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Schettini F; Medical Oncology Department, Hospital General of Granollers, Barcelona, Spain.
Cancer Immunol Immunother ; 72(6): 1725-1726, 2023 Jun.
Article em En | MEDLINE | ID: mdl-36809405
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article